Analys av HER2 i bröstcancer kvalitetssäkrad. Viktig behandlingsprediktiv och prognostisk faktor.
Fernö, Mårten LU ; Haglund, Monica ; Bendahl, Pär-Ola LU ; Olsson, Hans and Rydén, Lisa LU
(2008)
In Läkartidningen
105(32-33).
p.2181-2184
- Abstract
- Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or
amplified in 15-20% of all breast cancers, and is associated with an aggressive tumour type
with impaired prognosis and a predictive marker for trastuzumab treatment. HER2 status can
be determined by immunohistochemistry (IHC) at protein level and by fluorescence in situ
hybridisation (FISH) analysing gene amplification, and it is recommended that it should be
performed in all primary breast cancers. In a quality control study the reproducibility of HER2 status was assessed by distributing eleven breast tumours prepared on a tissue microarray to 25 pathology laboratories in Sweden in 2005 and 2006. The concordance between... (More) - Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or
amplified in 15-20% of all breast cancers, and is associated with an aggressive tumour type
with impaired prognosis and a predictive marker for trastuzumab treatment. HER2 status can
be determined by immunohistochemistry (IHC) at protein level and by fluorescence in situ
hybridisation (FISH) analysing gene amplification, and it is recommended that it should be
performed in all primary breast cancers. In a quality control study the reproducibility of HER2 status was assessed by distributing eleven breast tumours prepared on a tissue microarray to 25 pathology laboratories in Sweden in 2005 and 2006. The concordance between the laboratories indicated good reproducibility for IHC 2005 (kappa value 0.79) and very good reproducibility for 2006 (kappa value 0.86). The corresponding reproducibility for FISH was very good on both occasions (kappa value 0.92 and 0.96 respectively). A questionnaire indicated that 90% of all primary breast cancers diagnosed in Sweden in 2006 were tested for HER2 status. By way of summary, HER2 status is now implemented in clinical routine diagnostics in Sweden, and the present reproducibility study supports a high quality of testing. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1243228
- author
- Fernö, Mårten
LU
; Haglund, Monica
; Bendahl, Pär-Ola
LU
; Olsson, Hans
and Rydén, Lisa
LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Breast Neoplasms: drug therapy, Breast Neoplasms: metabolism, Breast Neoplasms: pathology, Immunohistochemistry: standards, In Situ Hybridization, Fluorescence: standards, Receptor, erbB-2: analysis, erbB-2: metabolism, Biological: analysis, Tumor Markers, Breast Neoplasms: diagnosis, Monoclonal: therapeutic use, Antibodies, Antineoplastic Agents: therapeutic use
- in
- Läkartidningen
- volume
- 105
- issue
- 32-33
- pages
- 2181 - 2184
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:18780693
- scopus:49649103523
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- id
- b45c9eb0-6ea7-45f7-8d78-2b19d94577cf (old id 1243228)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/18780693?dopt=Abstract
- http://ltarkiv.lakartidningen.se/artNo35403
- date added to LUP
- 2016-04-04 09:09:58
- date last changed
- 2022-01-29 08:33:40
@article{b45c9eb0-6ea7-45f7-8d78-2b19d94577cf,
abstract = {{Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or<br/><br>
amplified in 15-20% of all breast cancers, and is associated with an aggressive tumour type<br/><br>
with impaired prognosis and a predictive marker for trastuzumab treatment. HER2 status can<br/><br>
be determined by immunohistochemistry (IHC) at protein level and by fluorescence in situ<br/><br>
hybridisation (FISH) analysing gene amplification, and it is recommended that it should be<br/><br>
performed in all primary breast cancers. In a quality control study the reproducibility of HER2 status was assessed by distributing eleven breast tumours prepared on a tissue microarray to 25 pathology laboratories in Sweden in 2005 and 2006. The concordance between the laboratories indicated good reproducibility for IHC 2005 (kappa value 0.79) and very good reproducibility for 2006 (kappa value 0.86). The corresponding reproducibility for FISH was very good on both occasions (kappa value 0.92 and 0.96 respectively). A questionnaire indicated that 90% of all primary breast cancers diagnosed in Sweden in 2006 were tested for HER2 status. By way of summary, HER2 status is now implemented in clinical routine diagnostics in Sweden, and the present reproducibility study supports a high quality of testing.}},
author = {{Fernö, Mårten and Haglund, Monica and Bendahl, Pär-Ola and Olsson, Hans and Rydén, Lisa}},
issn = {{0023-7205}},
keywords = {{Breast Neoplasms: drug therapy; Breast Neoplasms: metabolism; Breast Neoplasms: pathology; Immunohistochemistry: standards; In Situ Hybridization; Fluorescence: standards; Receptor; erbB-2: analysis; erbB-2: metabolism; Biological: analysis; Tumor Markers; Breast Neoplasms: diagnosis; Monoclonal: therapeutic use; Antibodies; Antineoplastic Agents: therapeutic use}},
language = {{swe}},
number = {{32-33}},
pages = {{2181--2184}},
publisher = {{Swedish Medical Association}},
series = {{Läkartidningen}},
title = {{Analys av HER2 i bröstcancer kvalitetssäkrad. Viktig behandlingsprediktiv och prognostisk faktor.}},
url = {{http://www.ncbi.nlm.nih.gov/pubmed/18780693?dopt=Abstract}},
volume = {{105}},
year = {{2008}},
}